Hello,

My question is if the accuracy in dosing of afrezza inhalation powder will be affected if a

patient incurred a common cold, and had symptoms such as mucus and phlegm or

strep/other?

It seems inhalation of afreza could become inhibited which would be problematic for

patients and a concern among doctors.

Would this render the drug potentially less accurate than a needle or insulin pump?


I would like to know if these concerns have been addressed by Mannkind.



Regards,

Just curious as to what you all anticipate will happen in the near future with regards to the pps of pphm

It seems to me that a partnership between MNKD & NVO would be productive for both companies in accomplishing long-term goals and to getting Affrezza to FDA submission..

Just curious as to what extent (if any) you all believe MNKD could be affected...

According to a yahoo message board poster named "daviscupper" :

"Peter Brown runs the hedge fund, Renaissance Technologies. Renaissance has $24.8 billion in assets. Renaissance has invested $144 million into Novo Nordisk stock, a competitor of MannKind.

Peter Brown gets paid in excess of $5 million per year from Renaissance. He has a direct interest in seeing that Renaissance's investments do well. His compensation is directly tied to how well Renaissance performs.

Since Margaret Hamburg (FDA Chief) is married to Peter Brown she also benefits when Renaissance does well. This is a blantant conflict of interest."

http://online.wsj.com/article/SB124328188115551961.html?mod=WSJ_article_comments#articleTabs%3Darticle

http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_M/threadview?m=tm&bn=25210&tid=166937&mid=167136&tof=2&so=E&rt=2&frt=2&off=51

If massive dilution occurs along with other financing, I'm curious as to what the worst case scenario pps would look like before climbing back before approval submission date. I believe the lowest MNKD has seen was $1.74 but I could be incorrect. It certainly seems as if the pps could only go higher assuming a minimally dilutive method of funding is pursued along with upcoming trial results either before or after q4...

So, seeing as the stock has been climbing pps, do you all believe it is a buy, sell or hold as of today's close? Time is definately money in this maket.

Mannkind is definately running out of both...

I haven't sold yet because I recieved a nice buy in price, but i'm curious as to what your

opinions are? As of right now vs the near future for those who currently own stock in MNKD.